Résumé
An UPLC-Q-TOF/MSE technology coupled with UNIFI database was used to develop a rapid, high coverage, accurate and efficient chemical composition qualitative method for Xuezhikang Capsule. A UNIFI database was established utilizing compound name, formula, structure, following automatic matching with high-resolution mass numbers, isotope distributions, mass deviations, fragment ion matching, and chromatographic retention features in UNIFI database to achieve the qualitative results of natural products in Xuezhikang Capsules. Combined with manual confirmation, 82 chemical components were identified in Xuezhikang Capsules, and the MS2 fragmentation pathway of typical organic acids, flavonoids, monacrines, and monascus were analyzed to ensure accuracy of the LC-MS workflow. This study clarified the chemical substance basis of Xuezhikang Capsules by LC-MS technology, providing experimental data support for the identification of key quality attributes, quality control and consistency evaluation in the manufacturing process of Xuezhikang Capsules.
Résumé
Objective To assess the efficacy of Xuezhikang capsule on hyperuricacidemia and its safety. Methods The study was designed as a random, double-blind placebo controlled clinical trial. 80 hyperuricacidemia patients were divided randomly into test group and control group (40 in test group and 40 in control group). The course of treatment was 28 days. Results 75 patients finished the trial (38 in test group and 37 in control group). After 28 days of treatment, the differences in reduction of UA, XOD, FINs, Homa-IR, TC, TG, Lp, CRP, ET, ?2-MG and elevation of HDL of the test group were statistic significance. No side effect was found in the trial. Conclusion Xuezhikang capsule has good clinical effect and safety in the treatment of hyperuricacidemia.
Résumé
Objective: The purpose of this study was to further investigate other effects of Xuezhikang Capsule than blood lipid decreasing,particularly its effect on the high sensitivity C reactive protein(Hs-CRP) in young adult patients with hyperlipemia.Methods: We treated 135 hyperlipemia patients aged 18-39 years with Xuezhikang Capsule at 0.6g tid for 8 successive weeks,followed by detection of the levels of serum Hs-CRP and blood lipid.Results: After Xuezhikang treatment,the level of serum Hs-CRP was significantly decreased in the young adult patients with hyperlipemia(P
Résumé
Objective To observe the different effect of Xuezhikang Capsule on the patients of coronary heart disease (CHD) with abnormal blood lipid in different syndromes.Methods Of the 116 patients of CHD with abnormal blood lipid diagnosed by coronary arteriography and blood test, 30 were blood stasis syndrome, 23 phlegm turbid syndrome, 26 phlegm retention syndrome, and 37 non-phlegm non-stasis syndrome. Based on the standard treatment with modern medicine, Xuezhikang Capsule was given 0.6g each time, twice a day, for 24 weeks in succession.Results After the treatment, total cholesterol (TC), triglyceride (TG) and low density lipoprotein-C (LDL-C) were decreased (P
Résumé
AIM: To study the curative effect of Xuezhikang Capsule on non-alcoholic fatty liver disease accompanied by hyperlipidemia. METHODS: Small dosage of Xuezhikang Capsules had been administrated to the patients with non-alcoholic fatty liver disease accompanied by hyperlipidemia for 6 months. 32 healthy people had been chosen as control group at the same time. At the time points of before and after curing, body weight index. Type B ultrasonic, liver function, serum lipids, serum glucose and insulin levels had been tested. The McAuley index and the insulin resistance index of the homeostasis model assessment had been taken to evaluate insulin resistance. Liver biopsy had been conducted in some of the patients to compare the tissue changes before and after curing. RESULTS: After being treated with Xuezhikang Capsule, levels of insulin resistance serum lipids and ALT/AST in the patients with non-alcoliolic fatty liver disease had gone downward markedly. The histological observation in some of the patients had improved. No toxicity had been found. CONCLUSION: It is safe and potent to take the small dosage of Xuezhikang Capsule to cure the patients with non-alcoholic fatty liver disease accompanied by hyperlipidemia.